About the show
CrownCast, Crown Bioscience's podcast aims to discuss the emerging trends, breakthroughs, and viewpoints in oncology drug discovery, and development.
Newest episodes
Similar podcasts
All episodes
Syngeneic vs. Humanized Models: How to Choose the Right Model for Immuno-Oncology Research
9 min Video
Mastering Radiopharmaceutical Development - Preclinical Model Selection for Clinical Success
34 min Video
What if the next breakthrough in cancer treatment isn't a pill or infusion, but a precisely targeted radioactive payload that hunts down tumor cells like a guided missile? In this Smart Biotech Scientist Podcast episode, Dr. David Brühlmann speaks with Bryan Miller, Director of Scientific and Technical Operations at Crown Bioscience UK, about the radiopharmaceutical revolution transforming oncology. From theranostic approaches to advanced preclinical modeling, Miller shares insights on how this emerging therapeutic class is reshaping cancer treatment strategies.
Beyond Efficacy: Why DMPK and Toxicology Matter Earlier Than You Think
19 min Video
When people hear Crown Bioscience, they often think of world-class in vivo oncology models - and for good reason. But behind every successful oncology program is something just as critical: understanding how a drug behaves in the body and whether it can do so safely. In this CrownCast episode, host Michelle Dawn Mooney sits down with Rekha Pal, Senior Director of Scientific Engagement, and Santi Suryani Chen, Director of Business Development at Crown Bioscience, to explore where DMPK and toxicology fit into the drug discovery picture and how getting them right can save programs from costly detours.
ADC Development Revolution - Leveraging Translational Models for Next-Generation Cancer Therapeutics
24 min Video
Transforming Cancer Drug Development in the UK: Perspectives and Breakthroughs
24 min Video
Across the global oncology drug discovery landscape, the UK stands at the forefront. In this CrownCast episode, Rajendra Kumari, Executive Director of Integrated Solutions at Crown Bioscience, talks with Sarah Wagner, Senior Director of Business Development and Bryan Miller, Director of Scientific and Technical Operations about leveraging the UK’s vibrant ecosystem of cutting-edge technologies, strong collaborations, and a commitment to high ethical standards.
The Power and Potential of Biomarkers
18 min Video
Inside Oncology Drug Development: Overcoming Resistance with Science
38 min Video
In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that resistance often leads to disease relapse, severely impacting patient outcomes and quality of life. As we develop increasingly precise and powerful cancer therapies, how can we anticipate and overcome the inevitable challenge of drug resistance? In this episode of Crowncast, host Jonny McMichael, VP of Client Experience & Enablement at Crown Bioscience, speaks with Enrico Pesenti, the company’s Executive Director of Client Engagement. Together, they explore the evolving landscape of oncology drug resistance—unpacking the biological mechanisms behind it, the impact on patient care, and the technological breakthroughs helping researchers counter it. Main Points: Resistance in cancer therapy emerges through both genetic mutations and adaptive, non-genetic mechanisms, presenting a dynamic challenge for drug developers. New technologies—such as single-cell multi-omics, spatial transcriptomics, and CRISPR gene editing—are enabling deeper understanding and more precise modeling of resistance pathways. Translational models like organoids and patient-derived xenografts, combined with AI and machine learning, are helping design better, more personalized therapeutic strategies. Enrico Pesenti brings over two decades of experience in oncology research and drug development. He previously held leadership roles at Pharmacia and Nerviano and served as CEO of Accelera, a regulatory CRO in Italy. At Crown Bioscience, he leads scientific engagement, drawing on deep expertise in pharmacology and personalized cancer therapies.
Exploring Artificial Intelligence in Drug Discovery
40 min Video
Artificial intelligence is rapidly reshaping the drug discovery process, moving from augmenting research to actively driving innovation. As biotech companies face soaring R&D costs and long development cycles, AI promises a breakthrough: slashing drug development time by nearly half while improving accuracy in identifying promising compounds. With global pharmaceutical R&D spending projected to exceed $230 billion by 2026, efficiency isn't just desirable—it's critical. Can AI transition drug discovery from a serendipitous search to a precise, design-led process? And what are the real-world applications—and limitations—of machine learning in today’s labs? In this episode of Crowncast by Crown BioScience, host Jonny McMichael welcomes Kuan Yan, Senior Principal Scientist, and Jordan Lim, Associate Director of Digital Product. Together, they explore how AI is being used to automate workflows, optimize molecular designs, and provide advisory-level insights within CRO environments—all while navigating the complexities of regulation and data privacy. Key Highlights: AI is already accelerating early-stage drug discovery, from target identification to molecule generation and optimization—cutting development timelines dramatically. Human-in-the-loop remains essential, especially for quality control, validation, and navigating the risks of AI's "black box" nature. Crown BioScience is developing internal AI frameworks to transform data into insights, optimize experimental designs, and ultimately deliver more value to clients. Jordan Lim holds a bachelor’s and MBA from the University of California, San Diego, and brings a unique perspective from his work in patient advocacy, study coordination, and digital transformation at Crown BioScience. Kuan Yan earned his master’s and PhD in bioimaging and image analysis from the University of Leiden. With over 15 years of experience in machine learning, he now leads AI initiatives as a Senior Principal Scientist at Crown BioScience Nethe...
Navigating Challenges: Immune Cells vs. Cancer Cells
12 min Video
In the ever-evolving world of cancer treatment, immuno-oncology (IO) continues to stand at the forefront of innovation. With recent FDA approvals for TIL therapies and bispecific antibodies, and new developments in CAR-T technologies, the field is rapidly expanding into combination-based strategies that integrate with standard care. Researchers are also exploring how to overcome challenges posed by the tumor microenvironment and immune cell exhaustion to increase therapeutic success rates. How can scientists and biotech innovators harness the immune system more effectively to combat cancer—and what does the next generation of immuno-oncology look like? On this episode of Crowncast by Crown BioScience, host Jonny McMichael welcomes Gera Goverse, Director of Immuno-Oncology at Crown BioScience, for a deep dive into the scientific advances and strategic considerations shaping immuno-oncology today. From bispecifics and checkpoint inhibitors to personalized and allogeneic CAR-T therapies, they explore the complexity of immune response modeling, the need for combination therapies, and how the tumor microenvironment impacts treatment outcomes. Key discussion points from this episode: The rise of combination therapies and their role in overcoming immune resistance Emerging innovations in CAR-T design to address exhaustion and broaden application The critical importance of tumor microenvironment and model precision in preclinical research Dr. Gera Goverse is an accomplished immunologist with a PhD from Amsterdam UMC and a postdoctoral fellowship at KU Leuven. She has over a decade of experience in immunology and oncology, having transitioned from academia to biotech, where she now leads the immuno-oncology efforts at Crown BioScience Netherlands following their merger with organoid research CRO Ocello.
–
0 ratings from members
Rate this podcast
Log in to rate and review the shows you listen to.
No reviews yet — be the first member to rate "CrownCast".
This podcast, its content and its artwork are not owned by, affiliated with, or endorsed by Castquire.
Keep listening